FGFR1 and COVID-19: In either case, our overall findings show the possibility that small molecule inhibition of proteins encoded by fibroblast regulator genes (e.g., FGFR1, STAT3) may be a novel approach to the clinical management of COVID-19 cases, be it in the acute or postacute phase of critical illness.